In the case of Scherr Pharmaceuticals, Peter Noll faces the challenge of aligning two distinct business units—Siiquent and Teomik—each with their respective markets and revenue models. Isolde, head of Siiquent, targets hospitals and diagnostic labs, operating on a classic razor-blade model where the profit comes from selling consumables like chemical reagents and test kits. In contrast, Emanuel, head of Teomik, targets research institutions and universities, deriving profits primarily from high-margin machines and equipment. These business models reflect their respective markets: hospitals operate on slim margins and prefer cheaper consumables, while research institutions invest in durable, cutting-edge technology.
About the author
Related Posts
September 28, 2022
1A: Ethical Jobs
September 29, 2022
Would you accept a job at Facebook?
September 28, 2022
